SCHEMBL7493701

SCHEMBL7493701

N#Cc1ccc(NC(=O)Nc2ccccc2-c2ccccc2)c(NS(=O)(=O)c2ccccc2)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.51
SLC22A12 Q96S37 1/20 0.49
PTGES2 Q9H7Z7 2/20 0.48
CA12 O43570 2/20 0.47
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47
CA1 P00915 1/20 0.47
KAT6A Q92794 2/20 0.47
CXCR1 P25024 2/20 0.46
CXCR2 P25025 2/20 0.46
MCOLN3 Q8TDD5 2/20 0.46
LMNA P02545 1/20 0.46
ACLY P53396 4/20 0.46
CCR2 P41597 1/20 0.45
ALDH1A1 P00352 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GPR27 Q9NS67 2/20 0.43
AVPR2 P30518 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7490402 0.85 GPR27 (0.51) SLC22A12PTGES2CA12CA2CA9
SCHEMBL3709166 0.85 CXCR2 (0.63) SLC22A12PTGES2KAT6ACXCR1CXCR2
SCHEMBL7487824 0.85 TBXA2R (0.50) PTGES2CA12CA2CA9CA1
SCHEMBL7496445 0.85 ACLY (0.52) PTGES2CA12CA2CA9CA1
SCHEMBL7940030 0.85 HDAC1 (0.50) SLC22A12PTGES2KAT6ACXCR1CXCR2
SCHEMBL7923440 0.83 CA12 (0.50) STAT3SLC22A12PTGES2CA12CA2
SCHEMBL7487915 0.83 CXCR1 (0.45) SLC22A12PTGES2KAT6ACXCR1CXCR2
SCHEMBL7555940 0.83 SLC22A12 (0.52) SLC22A12PTGES2CXCR1CXCR2ACLY
SCHEMBL7491182 0.83 GPR27 (0.51) PTGES2KAT6ACXCR1CXCR2LMNA
SCHEMBL7487912 0.83 CXCR1 (0.45) SLC22A12PTGES2KAT6ACXCR1CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0896531-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-10-30 EP disclosed
US-20020128321-A1 IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2002-09-12 US disclosed
US-6262113-B1 HYDROXY- OR MERCAPTO-PHENYLUREAS SMITHKLINE BEECHAM CORPORATION 2001-07-17 US disclosed
US-6211373-B1 Phenyl urea antagonists of the IL-8 receptor SMITHKLINE BEECHAM CORPORATION 2001-04-03 US disclosed
EP-0896531-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-02-17 EP disclosed
US-5780483-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1998-07-14 US disclosed
WO-1997029743-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128321-A1 IL-8 receptor antagonists CXCL8, CCR8, IL1RN STAT3 222/4885SLC22A12 1654/4885PTGES2 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.